TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Composite Rate of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in The Clinician-Administered PTSD Scale (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PTSD Symptom Scale Self-Report- Civilian Version (PSS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Depression Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in The State Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skeletal Muscle Fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with a Rutgeerts score ≥ i2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alterations in the fallopian tube immune microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Less carcinogenic potential than control specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in transcriptome profile compared to control specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for unplanned procedural intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment related adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Severity Score of the Yale Global Tic Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COVID-19 disease incidence
Endpoint domain: Mortality/survival
Primary endpoint: ASIA Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of expression of blood biomarkers of air pollution exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: degree of fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum levels of IL-6, IL-8, IL-10, VEGF-A, Endostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Where Hilar Cholangiocarcinomas Could be Visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Rate Variation (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seropositivity for Anti-NoV GI.1 and GII.4 VLP Antibodies on Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity for Anti-NoV GI.1 and GII.4 VLP Antibodies on Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity for Anti-NoV GI.1 and GII.4 VLP Antibodies on Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tourniquet inflation pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to set the tourniquet inflation pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum FGL2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in number of active trigger points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Future adverse cardiovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of women with normal vaginal flora who developed AVF/BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of women with AVF/BV whose infection was eradicated following antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of women with AVF/BV who restored normal vaginal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Recommended Phase II Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum creatinine to 2 times the baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Quality of Caregiver-Child Language Interaction
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in Parent/Provider Expectations and Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in MacArthur-Bates Communication Development Inventories (MBCDI)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intracellular magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of vaginal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IgM, IgG and proliferative response to HA vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative in-hospital atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Falls Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of germline BAP1 variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical phenotypes in at risk blood-line family members
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral bioavailability of veliparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of blood sample collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Global Impression Severity Scale (CGI-S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in sputum neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability to perform lung ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety Disorders Interview Schedule for DSM-IV-Child Version (ADIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell responses to GEN-009 adjuvanted vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Signs of Limbal Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transpulmonary pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: proportion of patients complaining of abdominal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in TOMM20 expression by IHC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MCT4 expression in fibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective response rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Integration Success of Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Genital tract CD4 cells expressing CCR5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of exacerbations per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Occurrence rate of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Arbaclofen Placarbil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration of Arbaclofen Placarbil (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Plasma Concentration of Arbaclofen Placarbil (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoinflammatory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antioxidant / oxidant parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemia / reperfusion injury parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asymmetry of EEG extracted indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Cerebral Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Change in Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of Change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pittsburgh sleep quality index (PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Overall Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Handling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of participants retained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-month PFS rate
Endpoint domain: Mortality/survival
Primary endpoint: mPFS
Endpoint domain: Mortality/survival
Primary endpoint: Toxic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in defecation routine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in severity of symptoms of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in quality of life due to constipation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Developed Surgical Site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Net adverse clinical event (NACE)
Endpoint domain: Adverse events/effects
Primary endpoint: ICDs' intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in maximum walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cycles on Which Grade 3 or Higher Adverse Events Coded According to CTC AE Version 5 Were Observed
Endpoint domain: Adverse events/effects
Primary endpoint: Myocardial Perfusion at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skeletal Muscle Perfusion During Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence and type of abnormalities on neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Patients With Endoscopically Detectable-telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactical Driving Quotient (TDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Inpatient Time Required to Achieve Delivery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Normalization of genetic-brain-cognition function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients who develop de-novo DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in arterial spin labelling (ASL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cerebrovascular outcomes
Primary endpoint: Changes from baseline in gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes from baseline in concentration of short chain fatty acids in stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes from baseline in bowel movements with respect to number of bowel movements and stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes from baseline in blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in blood insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Slope in estimated glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnostic accuracy of reflectance confocal scanning laser microscopy for melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connectivity between amygdala and hippocampus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retention Rate of Zonisamide (ZNS)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: short-term safety
Endpoint domain: Adverse events/effects
Primary endpoint: Response Evaluation Criteria in Solid Tumors (RECIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Assessment in Neuro-Oncology (RANO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall mortality at one year
Endpoint domain: Mortality/survival
Primary endpoint: Infection rate of Anesthesiologist
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of subacute occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-life (t½λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-curve From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC(0-last))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological progression free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in frequency of hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in binding of the serotonin transporter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful Pulmonary Vein Isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: average pain scores at rest and at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Little's Index of Irregularity (LII)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial Bolton's Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Bolton's Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth-size-arch-length-discrepancy (TSALD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in VFQ-25 survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in GHQ-12 survey scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in PHQ-9 survey scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First go Insertion Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: First go Successful Ventilation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Complication Free Insertions
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of HPV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of HPV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Allocated to Each ISA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients with no graft failure at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active ankle range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With 50% or Greater Reduction in Overall Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone biomarkers levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Microbiome Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consensus in therapeutic decisions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of Major Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Clinically Relevant Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Nuisance Bleeding Event
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of myocardial edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tablet release
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of appropriate sensing and pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious adverse device effects (SADEs) related to the SD01 lead
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-related Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Abnormal Vital Signs Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Abnormal Electrocardiogram Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in physiological data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biomechanical data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of Endoscopy and MRI screening for NPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold change of IELT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 Year Relapse Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in total Hamilton Depression Rating Scale (HAM-D17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montgomery-Åsberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After 13vPnC Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) From Before 13vPnC Vaccination to 1 Month After 13vPnC Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain score during cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of end milk weight expressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First time of rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with heterogeneous PET/CT activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GI calculation for the composite meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes